Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
38.57 USD | +0.34% | +5.96% | +50.82% |
03/05 | Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53 | MT |
02/05 | Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.82% | 2.36B | |
+22.17% | 46.4B | |
-1.70% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+9.95% | 26.01B | |
-19.62% | 19.52B | |
+29.90% | 12.43B | |
-0.26% | 12.18B | |
-0.76% | 12.13B |
- Stock Market
- Equities
- KYMR Stock
- News Kymera Therapeutics, Inc.
- Kymera Therapeutics : Presents Preclinical Data for Anti-Inflammatory Drug KT-474